Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Evering TH, et al. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39252866 Free PMC article.
Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium.
McCleary NJ, Merle JL, Richardson JE, Bass M, Garcia SF, Cheville AL, Mitchell SA, Jensen R, Minteer S, Austin JD, Tesch N, DiMartino L, Hassett MJ, Osarogiagbon RU, Wong S, Schrag D, Cella D, Smith AW, Smith JD; IMPACT Consortium. McCleary NJ, et al. JAMIA Open. 2024 Sep 4;7(3):ooae081. doi: 10.1093/jamiaopen/ooae081. eCollection 2024 Oct. JAMIA Open. 2024. PMID: 39234146 Free PMC article.
Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial.
Paudel R, Enzinger AC, Uno H, Cronin C, Wong SL, Dizon DS, Hazard Jenkins H, Bian J, Osarogiagbon RU, Jensen RE, Mitchell SA, Schrag D, Hassett MJ. Paudel R, et al. Among authors: hazard jenkins h. J Natl Cancer Inst. 2024 Jul 1;116(7):1137-1144. doi: 10.1093/jnci/djae049. J Natl Cancer Inst. 2024. PMID: 38445744 Free PMC article. Clinical Trial.
Communication with physicians and family about breast Cancer recurrence.
Kelly KM, Rai P, Studts JL, Dickinson S, Henschel B, Dignan M, Chambers M, Hazard-Jenkins H. Kelly KM, et al. Among authors: hazard jenkins h. PEC Innov. 2023 Nov 28;3:100237. doi: 10.1016/j.pecinn.2023.100237. eCollection 2023 Dec 15. PEC Innov. 2023. PMID: 38148854 Free PMC article.
Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials.
Smith AW, DiMartino L, Garcia SF, Mitchell SA, Ruddy KJ, Smith JD, Wong SL, Cahue S, Cella D, Jensen RE, Hassett MJ, Hodgdon C, Kroner B, Osarogiagbon RU, Popovic J, Richardson K, Schrag D, Cheville AL; IMPACT Consortium. Smith AW, et al. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad073. doi: 10.1093/jncics/pkad073. JNCI Cancer Spectr. 2023. PMID: 37930033 Free PMC article.
Educational Case: Hereditary breast and ovarian cancers.
Givi JP, Hazard-Jenkins HW, Flanagan M. Givi JP, et al. Among authors: hazard jenkins hw. Acad Pathol. 2023 Sep 7;10(3):100091. doi: 10.1016/j.acpath.2023.100091. eCollection 2023 Jul-Sep. Acad Pathol. 2023. PMID: 37719445 Free PMC article. No abstract available.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA, Currier JS, Eron JJ, Javan AC, Bender Ignacio R, Margolis D, Zhu Q, Ma J, Zhong L, Yan L, D'Andrea Nores U, Hoover K, Mocherla B, Choudhary MC, Deo R, Ritz J, Fischer WA, Fletcher CV, Li JZ, Hughes MD, Smith D, Daar ES; ACTIV-2/A5401 Study Team. Evering TH, et al. Ann Intern Med. 2023 May;176(5):658-666. doi: 10.7326/M22-3428. Epub 2023 Apr 18. Ann Intern Med. 2023. PMID: 37068272 Free PMC article. Clinical Trial.
20 results